Results of DECIDE registry presented at SCCT 2025 - Cardiovascular News

Heartflow’s Plaque Analysis for CAD Management Evaluated in DECIDE Registry - Cardiac Interventions Today

July 21, 2025—Heartflow, Inc. recently announced new data, including final primary endpoint data from the DECIDE registry, for its Heartflow Plaque Analysis. DECIDE is a prospective study enrolling approximately 20,000 patients at more than 30 sites across the United States. The primary endpoint for the registry is changes in medical management after Heartflow Plaque Analysis. Clinical outcomes and biomarkers are the secondary endpoints. Safety …

Results of DECIDE registry presented at SCCT 2025 - Cardiovascular News

Heartflow has announced new data for its artificial intelligence (AI)-enabled Heartflow Plaque Analysis, including final primary endpoint data from the DECIDE registry. Data from the DECIDE registry showed Heartflow Plaque Analysis led to medical management change in over half of patients beyond coronary computed tomography angiography (CCTA) alone, regardless of traditional risk factors or CCTA findings. The DECIDE registry is the largest prosp…